Company intelligence / Profile preview
Sunstate Biosciences
Monrovia, California, United Statessunstatebiosciences.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
The company has brought its lead program, a single protein encapsulated doxorubicin nanodrug, to Phase 1 clinical trials for neoplasms. Multiple preclinical programs, including those targeting HER2-positive breast cancer and other cancers, are advancing on the same platform. Early data suggests reduced cardiotoxicity and increased efficacy versus conventional doxorubicin.
- Therapeutic areas
- Oncology
- Modalities
- Small moleculeNanoparticle
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on Sunstate Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sunstate Biosciences.